Genetic changes in small cell lung carcinoma
Clin. transl. oncol. (Print)
; 10(4): 189-197, abr. 2008. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-123433
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Small cell lung carcinoma (SCLC) accounts for approximately 15% of all lung cancer cases. Despite a frequently good response to first-line treatment with chemotherapy and/or radiotherapy, early relapse occurs in the majority of patients and 5-year survival is only about 5%. Therefore, there is a need to develop novel treatments to improve the outcome of patients with SCLC. To fulfil this need, it is critical to gain further understanding on the molecular basis of SCLC and specifically to identify novel therapeutic targets. Clinical trials with molecularly targeted agents have been performed with little success in the past, but recently many promising oncogenic pathways have been discovered and novel targeted therapies are under evaluation. In this review, we summarise the most relevant genetic and signalling pathway alterations reported to date in SCLC and discuss the potential therapeutic implications of such events (AU)
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Ensaios Clínicos como Assunto
/
Carcinoma de Células Pequenas
/
Neoplasias Pulmonares
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2008
Tipo de documento:
Artigo
Instituição/País de afiliação:
Fundación Jiménez Díaz/Spain
/
Hospital del Mar/Spain